shr-2005
mAbexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Nov 28, 2023 (NCT06108492)
Timeline
2020s
- Jan 1, 2023
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- UnclearUnclear
Unclear unclear
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06588179 | Phase 1/Phase 2 (Phase 2) | Oct 1, 2024 | Fudan University |
| NCT06108492 | Phase 1 | Nov 28, 2023 | Hengrui Therapeutics, Inc. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Fudan University | Academic/Hospital | 1 | 1 | 1 | 2024 |
| Hengrui Therapeutics, Inc. | For profit | 1 | 1 | 1 | 2023 |
2 organizations
Page 1 / 1